NICE rejects Zykadia (ceritinib) to treat ALK+ metastatic non-small cell lung cancer- Novartis
The UK's National Institute for Health and Care Excellence (NICE) does not recommend Zykadia (ceritinib) from Novartis, for use in ALK+ metastatic non-small cell lung cancer patients who have progressed on or are intolerant to Xalkori (crizotinib). This decision was made despite the drug receiving the status of "promising innovative medicine" with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Also patients will not be able to access ceritinib through the Cancer Drugs Fund, which pays for some oncology treatments that would otherwise be considered not cost-effective.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins